Karyopharm Therapeutics Inc. and Clinipace Worldwide Announce Preferred Provider Agreement
Clinipace Worldwide announced it has entered into a preferred provider agreement with Karyopharm Therapeutics Inc.
Clinipace Worldwide announced it has entered into a preferred provider agreement with Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The preferred provider agreement is part of a longer-term strategic partnership that would see Clinipace managing several clinical programs, including oncology, wound healing, and other diseases, on behalf of Karyopharm in 2014.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
